• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

    10/30/24 7:00:00 AM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LRMR alert in real time by email
    • Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich's ataxia (FA) receiving 25 mg of nomlabofusp daily for 30-180 days in ongoing open label extension (OLE) study
    • Initiation of PK run-in study in adolescents on track by year-end 2024
    • Initiation of global confirmatory/registration study planned mid-2025
    • Biologics License Application (BLA) submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval
    • Strong balance sheet of $203.7 million cash, cash equivalents and marketable securities as of September 30, 2024, with projected cash runway into 2026

    BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2024 operating and financial results.

    "Our nomlabofusp program continues to advance, with the potential to be the first frataxin protein replacement therapy for patients with FA. All sites are activated with ongoing enrollment in our OLE study evaluating the long-term safety, PK and frataxin levels in patients with FA following daily subcutaneous administration. In mid-December, we plan to provide a development program update that will include available safety, PK, and frataxin data from patients receiving 25 mg of nomlabofusp daily for up to 180 days in our OLE study. We expect to also provide an update on enrollment," said Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar. "In November, we look forward to presenting at the International Congress for Ataxia Research (ICAR) meeting new data on results from our completed dose exploration study including exploratory gene and lipid expression results following nomlabofusp treatment. In addition, we will also be presenting two posters with data from patients participating in our Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies and Phase 2 dose exploration study. One poster will provide patient data on baseline disease characteristics and baseline tissue frataxin levels, and the other will present the relationship between dose, PK and tissue frataxin levels using modeling and simulation. We remain on track to initiate a PK run-in study in adolescent patients with FA in the fourth quarter of this year which is the first step towards evaluating nomlabofusp treatment in pediatric patients."

    Dr. Ben-Maimon continued, "On the regulatory front, we were pleased to recently receive Innovative Licensing and Access Pathway (ILAP) designation from the Medicines and Healthcare Products Regulatory Agency (MHRA) which aims to facilitate patient access by accelerating time to market in the U.K. We also held our first meetings with the Food and Drug Administration (FDA) as part of the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program and appreciate the dialogue and interaction designed to help advance our development program. In parallel, we began work to further understand the continued areas of unmet need in the FA therapeutic landscape from the perspective of physicians, payers, and most importantly, patients. We will use this information to develop our commercial approach and to refine our market entry strategy. Finally, we continue scaling up our manufacturing efforts and collecting required data to support a potential accelerated approval path. Our targeted BLA submission remains on track for the second half of 2025."

    Recent Highlights

    • Today, Larimar announced that it will provide a nomlabofusp development program update in mid-December 2024 that will include available safety, PK and frataxin data, as well as available clinical outcomes observations from patients currently receiving a daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the OLE study. An update on enrollment in the OLE study will also be provided.
    • Larimar recently received ILAP designation from the MHRA for nomlabofusp for the treatment of adults and children with FA. ILAP aims to facilitate patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with U.K. regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (EU), Fast Track and Rare Pediatric Disease designations in the U.S., PRIME designation in the EU, and selected to be in the START pilot program by the FDA.
    • Larimar is on track to initiate by year-end a PK run-in study in an initial cohort of 12-15 adolescents (12 to 17 years of age) with FA. Initiation of a second cohort of 12-15 children (2 to 11 years of age) is planned to follow next year. Study participants will be randomized 2:1 to receive either nomlabofusp or placebo daily. Following assessment of safety and exposure data of each cohort in the PK run-in study, participants will be eligible to screen for the OLE study.
    • Larimar is on track for a planned initiation of a global confirmatory/registration study planned mid-2025 with potential sites in the U.S., Europe, U.K., Canada, and Australia. Larimar continues to target BLA submission for the second half of 2025 to support accelerated approval.
    • In September 2024, Larimar announced that data from the Company's nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the ICAR meeting being held November 12-15, 2024, in London, U.K.

    Third Quarter 2024 Financial Results

    As of September 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $203.7 million, which provides projected cash runway into 2026.

    Third quarter of 2024 compared to the third quarter of 2023

    The Company reported a net loss for the third quarter of 2024 of $15.5 million, or $0.24 per share, compared to a net loss of $9.1 million, or $0.21 per share, for the third quarter of 2023.

    Research and development expenses for the third quarter of 2024 were $13.9 million compared to $6.6 million for the third quarter of 2023. The increase in research and development expenses was primarily driven by an increase of $3.8 million in nomlabofusp manufacturing costs including lyophilization development, production scaling costs and manufacturing costs related to producing doses to be used in ongoing and planned clinical trials, an increase of $1.1 million in personnel expense due to increased headcount, an increase of $0.9 million in assay development costs, an increase of $0.6 million in clinical costs primarily associated with the OLE study which began dosing patients in the first quarter of 2024, an increase of $0.3 million of professional fees related to consulting costs, an increase of $0.2 million in stock compensation costs associated with 2024 grants and an increase of $0.2 million in internal lab costs.

    General and administrative expenses were $4.3 million in the third quarter of 2024 compared to $3.8 million in the third quarter of 2023. The increase in general and administrative expenses was primarily driven by an increase of $0.4 million in personnel expense and an increase of $0.2 million in professional fees primarily related to consulting costs related to commercial activity and other public company related expenses.

    Nine months ended September 30, 2024 compared to the nine months ended September 30, 2023

    The Company reported a net loss for the 9-month period ending September 30, 2024 of $51.8 million, or $0.86 per share, compared to a net loss of $24.0 million, or $0.55 per share, for the 9-month period ending September 30, 2023.

    Research and development expenses for the 9-month period ending September 30, 2024 were $46.5 million compared to $17.0 million for the 9-month period ending September 30, 2023. The increase in research and development expenses was primarily driven by an increase of $20.2 million in nomlabofusp manufacturing costs including lyophilization development, production scaling costs and manufacturing costs related to producing doses to be used in ongoing and planned clinical trials, an increase of $3.2 million in personnel expense due to increased headcount, an increase of $2.9 million in clinical costs primarily associated with the OLE study which began dosing patients in the first quarter of 2024, increase of $0.9 million in assay development costs, an increase of $0.8 million related to the Track-FA program, an increase of $0.5 million in stock compensation costs associated with 2024 grants, an increase of $0.5 million in internal lab costs and an increase of $0.3 million of professional fees related to consulting costs.

    General and administrative expenses for the 9-month period ending September 30, 2024 were $13.1 million compared to $10.6 million for the 9-month period ending September 30, 2023. The increase in general and administrative expenses was primarily driven by an increase of $1.0 million in personnel expense, an increase of $1.0 million in professional fees primarily related to consulting costs related to commercial activity and other public company related expenses, an increase of $0.3 million of other expense related to computer software, information technology services and recruiting and an increase of $0.2 million in stock compensation costs associated with 2024 grants.

    About Larimar Therapeutics

    Larimar Therapeutics, Inc. (NASDAQ:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar's ability to develop and commercialize nomlabofusp and other planned product candidates, Larimar's planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plan and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar's product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar's nomlabofusp development strategy; the potential impact of public health crises on Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar's ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp's manufacturing process; Larimar's ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar's management's views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

    Investor Contact:                                                        

    Joyce Allaire                                                                

    LifeSci Advisors                                                        

    [email protected]                                                 

    (212) 915-2569

    Company Contact:

    Michael Celano        

    Chief Financial Officer

    [email protected]

    (484) 414-2715

                            

    Larimar Therapeutics, Inc.
    Condensed Consolidated Balance Sheet
    (unaudited)
      September 30, December 31,
      2024 2023
    Assets    
    Current assets:    
    Cash and cash equivalents $35,067  $26,749 
    Short-term marketable securities  168,640   60,041 
    Prepaid expenses and other current assets  9,549   3,385 
    Total current assets  213,256   90,175 
    Property and equipment, net  779   684 
    Operating lease right-of-use assets  3,026   3,078 
    Restricted cash  1,339   1,339 
    Other assets  621   659 
    Total assets $219,021  $95,935 
    Liabilities and Stockholders' Equity    
    Current liabilities:    
    Accounts payable $1,686  $1,283 
    Accrued expenses  13,573   7,386 
    Operating lease liabilities, current  1,026   837 
    Total current liabilities  16,285   9,506 
    Operating lease liabilities  4,336   4,709 
    Total liabilities  20,621   14,215 
    Commitments and contingencies    
    Stockholders' equity:    
        Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023  —   — 
        Common stock, $0.001 par value per share; 115,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 63,806,628 and 43,909,069 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively  64   43 
    Additional paid-in capital  438,312   270,150 
    Accumulated deficit  (240,334)  (188,554)
    Accumulated other comprehensive gain  358   81 
    Total stockholders' equity  198,400   81,720 
    Total liabilities and stockholders' equity $219,021  $95,935 
             



    Larimar Therapeutics, Inc.
    Condensed Consolidated Statements of Operations
    (In thousands, except share and per share data)
    (unaudited)
             
      Three Months Ended September 30, Nine Months Ended September 30,
      2024 2023 2024 2023
    Operating expenses:        
    Research and development $13,919  $6,585  $46,540  $17,022 
    General and administrative  4,345   3,754   13,057   10,574 
    Total operating expenses  18,264   10,339   59,597   27,596 
    Loss from operations  (18,264)  (10,339)  (59,597)  (27,596)
    Other income, net  2,765   1,275   7,817   3,640 
    Net loss $(15,499) $(9,064) $(51,780) $(23,956)
    Net loss per share, basic and diluted $(0.24) $(0.21) $(0.86) $(0.55)
    Weighted average common shares outstanding, basic and diluted 63,806,158   43,903,738   60,399,697   43,899,670 
    Comprehensive loss:        
    Net loss $(15,499) $(9,064) $(51,780) $(23,956)
    Other comprehensive gain (loss):        
    Unrealized gain (loss) on marketable securities  508   (5)  277   38 
    Total other comprehensive gain (loss)  508   (5)  277   38 
    Total comprehensive loss $(14,991) $(9,069) $(51,503) $(23,918)


    Primary Logo

    Get the next $LRMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LRMR

    DatePrice TargetRatingAnalyst
    1/29/2025$18.00Buy
    Truist
    10/16/2024$26.00Outperform
    Oppenheimer
    10/3/2024$22.00Outperform
    Wedbush
    10/2/2024$15.00Buy
    H.C. Wainwright
    9/4/2024$16.00Outperform
    Robert W. Baird
    4/3/2024$25.00Outperform
    Leerink Partners
    11/17/2023$4.50Neutral → Buy
    Citigroup
    10/19/2022$12.00Buy
    Guggenheim
    More analyst ratings

    $LRMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Development Officer Shankar Gopi was granted 23,306 shares, increasing direct ownership by 85% to 50,806 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      1/24/25 4:16:59 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Clayton Russell was granted 23,306 shares, increasing direct ownership by 104% to 45,806 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      1/24/25 4:16:21 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Ben-Maimon Carole was granted 91,000 shares, increasing direct ownership by 31% to 387,208 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      1/24/25 4:15:42 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Larimar Therapeutics Reports First Quarter 2025 Financial Results

      FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent PK run-in study; topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025 Strong balance sheet of $157.5 million cash, cash equivalents and marketable securities as of March 31, 2025, with projected cash runway into second quarter of 2026 BALA CYNWYD, Pa., April 30, 2025 (GLOBE NEWSWIRE

      4/30/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approvalFDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as heart, dorsal root ganglia and skeletal muscleLarimar is continuing discussions with FDA on the adequacy of the safety data set to support BLA submission BLA seeking accelerated approval targeted for submission by year-end 2025FDA

      3/24/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

      BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025. Details on the presentation can be found below. Date: Monday, March 10, 2025Time: 3:40 – 4:10 PM ESTWebcast Link: https://wsw.com/webcast/leerink38/lrmr/2247553 Following the conclusion of the presentation, a replay will be available for 30 days on the "Events an

      3/3/25 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LRMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hamilton Thomas Edward bought $499,998 worth of shares (57,208 units at $8.74), increasing direct ownership by 11% to 564,798 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/31/24 4:56:58 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flynn James E bought $37,499,993 worth of shares (4,290,617 units at $8.74) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/16/24 2:37:50 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thomas Frank E bought $22,000 worth of shares (2,000 units at $11.00) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/15/24 4:21:16 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Larimar Therapeutics with a new price target

      Truist initiated coverage of Larimar Therapeutics with a rating of Buy and set a new price target of $18.00

      1/29/25 7:39:50 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Larimar Therapeutics with a new price target

      Oppenheimer initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $26.00

      10/16/24 7:29:15 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Larimar Therapeutics with a new price target

      Wedbush initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $22.00

      10/3/24 7:34:56 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    SEC Filings

    See more
    • Larimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

      5/5/25 6:33:44 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Larimar Therapeutics Inc.

      10-Q - Larimar Therapeutics, Inc. (0001374690) (Filer)

      4/30/25 5:06:58 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

      4/30/25 7:01:42 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $LRMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 5:05:19 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 11:41:09 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 9:16:35 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

      BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company's Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in regulatory and clinical strategy. "Dr. Sherman is a pharmaceutical industry veteran who brings decades of leadership experience in global regulatory and clinical strategy to our Board of Directors.

      10/3/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

      Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 dataTop-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024 BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Lari

      8/10/23 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

      BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell "Rusty" Clayton, DO, as Chief Medical Officer ("CMO"), effective today. Dr. Clayton succeeds former CMO Nancy M. Ruiz, MD, who is retiring and will provide consulting support to the Company as needed. "We are delighted to welcome Dr. Clayton in his new role as CMO as we further expand our clinical development of CTI-1601. Rusty has been one of our closest advisors for the last 5 years, has attended every meeting between Larimar and the FDA, in

      7/17/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Financials

    Live finance-specific insights

    See more
    • Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

      Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) studyTissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90Tissue FXN levels increased and were maintained over time, with mean levels increasing from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90Early trends towards improvement in clinical outcomes were observed at Day 90, supporting the potential that nomlabofusp administration may result in a clinical benefit across a broad spectrum of patient

      12/16/24 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

      Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse eventsDose dependent increases in frataxin levels were observed in skin and buccal cells Open Label Extension (OLE) study initiated in January 2024 to dose 25 mg daily of nomlabofusp with dosing anticipated to be starting later this quarter; Initial data expected in Q4 2024Initiated discussions with the FDA on use of tissue frataxin levels as a novel surrogate endpoint to support a potential Biologics License Application ("BLA") submission for accelerated approval targeted for 2H 2025 Company management to host webcast and conference call today a

      2/12/24 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

      Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024Company management hosting a webcast and conference call today at 8:00 a.m. ET BALA CYNWYD, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601 i

      7/25/23 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care